I et central fase- III lever- studie var den gennemsnitlige sensitivitet ved kombineret præ - og post - kontrastforstærket MR- scanning for patienter behandlet med Gadovist 79% og specifikt 81% for påvisning af læsioner og klassificering af mistænkte maligne leverlæsioner (patient- baseret analyse).
In a pivotal phase III liver study average sensitivity in combined pre and postcontrast MRI for Gadovist-treated patients was 79% and specificity was 81% for lesion detection and classification of suspected malignant liver lesions (patientbased analysis).